DCT

1:26-cv-11697

Eisai R&D Management Co Ltd v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Eisai R&D Management Co., Ltd. v. Zydus Pharmaceuticals (USA) Inc., 1:26-cv-11697, D.N.J., 09/10/2026
  • Venue Allegations: Venue is asserted based on Defendant Zydus USA residing and being incorporated in New Jersey, having a regular and established place of business in the district, and committing alleged acts of infringement within the district.
  • Core Dispute: Plaintiffs allege that Defendants’ submission of a 505(b)(2) New Drug Application to the U.S. Food and Drug Administration (“FDA”) for a generic version of Plaintiffs' LENVIMA® (lenvatinib) capsules constitutes an act of infringement of four U.S. patents covering high-purity compositions and methods of treating cancer.
  • Technical Context: The technology relates to lenvatinib, a small-molecule kinase inhibitor used as an oral chemotherapy agent for various cancers, a significant segment of the multi-billion dollar oncology market.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Zydus’s submission of a 505(b)(2) application (No. 220262) and its subsequent service of a Paragraph IV Notice Letter on the Plaintiffs, stating its intent to market a generic version of LENVIMA® prior to the expiration of the patents-in-suit. The parties failed to reach an agreement on an Offer of Confidential Access (“OCA”) to the 505(b)(2) application materials prior to the complaint's filing.

Case Timeline

Date Event
2006-05-18 ’256 Patent Priority Date
2014-08-28 ’393 and ’547 Patents Priority Date
2015-02-13 FDA Approval of LENVIMA® (NDA No. 206947)
2015-04-14 ’256 Patent Issue Date
2017-05-16 ’409 Patent Priority Date
2019-09-10 ’393 Patent Issue Date
2021-11-30 ’547 Patent Issue Date
2025-02-18 ’409 Patent Issue Date
2026-07-30 Zydus sends Paragraph IV Notice Letter
2026-07-31 Eisai Inc. receives Paragraph IV Notice Letter
2026-08-03 Eisai R&D Management Co. receives Paragraph IV Notice Letter
2026-09-10 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,006,256 - “Antitumor Agent for Thyroid Cancer”, issued April 14, 2015

The Invention Explained

  • Problem Addressed: The patent identifies a need for therapeutic agents to treat diseases associated with RET kinase activity, such as various forms of thyroid cancer ’256 Patent, col. 2:1-12
  • The Patented Solution: The invention claims a method of treating thyroid cancer by administering an effective amount of an RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, which is the chemical name for lenvatinib ’256 Patent, abstract ’256 Patent, col. 4:10-23 The patent provides data showing this substance inhibits RET kinase activity and has an antitumor effect in a model for human medullary thyroid carcinoma (e.g., ’256 Patent, FIG. 2).
  • Technical Importance: The invention provides a targeted therapy approach for thyroid cancer by identifying a specific molecular target (RET kinase) and a compound that inhibits it, moving beyond traditional, less-specific chemotherapies.

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the ’256 patent Compl. ¶51 Independent claim 1 is asserted.
  • Essential elements of independent claim 1:
    • A method for treating thyroid carcinoma in a patient in need thereof,
    • comprising administering to the patient an effective amount of an RET kinase inhibiting substance,
    • wherein the RET kinase inhibiting substance is a compound represented by General Formula (I) or a pharmacologically acceptable salt thereof or a solvate thereof.

U.S. Patent No. 10,407,393 - “High-Purity Quinoline Derivative and Method for Manufacturing Same”, issued September 10, 2019

The Invention Explained

  • Problem Addressed: The patent discloses that prior art methods for producing lenvatinib, a quinoline derivative, also produce impurities such as the compound of formula (I) that are difficult to remove through common purification methods like chromatography and crystallization ’393 Patent, col. 4:1-9
  • The Patented Solution: The invention is a composition of matter comprising lenvatinib (formula IV) or a salt thereof that is highly pure. This purity is defined by having a very low content of a specific impurity, compound (I), specifically "350 ppm by mass or less" ’393 Patent, abstract The patent describes a novel production method to achieve this high level of purity ’393 Patent, col. 4:61-67
  • Technical Importance: For pharmaceutical active ingredients, achieving high purity and minimizing specific, potentially genotoxic impurities is critical for regulatory approval and patient safety.

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the ’393 patent Compl. ¶60 Independent claim 1 is asserted.
  • Essential elements of independent claim 1:
    • A compound represented by formula (IV) or a salt thereof,
    • wherein the content of a compound represented by formula (I) is 350 ppm by mass or less.

Multi-Patent Capsule: U.S. Patent No. 11,186,547 - “High-Purity Quinoline Derivative and Method for Manufacturing Same”, issued November 30, 2021

  • Technology Synopsis: The patent addresses the problem of impurities generated during the synthesis of lenvatinib ’547 Patent, col. 4:5-13 The solution is a highly pure composition of lenvatinib (formula IV) or its salt, specifically defined as containing 350 ppm by mass or less of the impurity represented by formula (I) ’547 Patent, abstract ’547 Patent, claim 1
  • Asserted Claims: The complaint generally asserts infringement of one or more claims Compl. ¶69 The independent composition claims, such as claim 1, are the likely focus.
  • Accused Features: The composition of Zydus’s proposed generic product is alleged to meet the purity limitations of the patent Compl. ¶70

Multi-Patent Capsule: U.S. Patent No. 12,226,409 - “Treatment of Hepatocellular Carcinoma”, issued February 18, 2025

  • Technology Synopsis: The patent addresses the treatment of unresectable hepatocellular carcinoma (HCC) ’409 Patent, col. 1:19-21 The invention provides specific methods of treatment using lenvatinib, detailing dosage regimens based on patient body weight and specific protocols for dose modification upon the occurrence of various adverse events ’409 Patent, abstract
  • Asserted Claims: The complaint generally asserts infringement of one or more claims Compl. ¶78 The independent method claims, such as claim 1, are the likely focus.
  • Accused Features: Zydus's submission of its 505(b)(2) application is alleged to be an act of infringement because its proposed product label will instruct medical professionals to administer the drug according to the patented methods for treating HCC Compl. ¶¶77-81

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are "Zydus's Proposed 505(b)(2) Products," which are the subject of 505(b)(2) New Drug Application No. 220262 Compl. ¶14

Functionality and Market Context

  • The complaint alleges these products are generic versions of Plaintiffs' LENVIMA® (lenvatinib) oral capsules Compl. ¶36 Compl. ¶43 Lenvatinib is a kinase inhibitor approved for treating multiple types of cancer, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma Compl. ¶37 Zydus is seeking FDA approval to commercially manufacture, use, and sell its proposed products in the United States prior to the expiration of the patents-in-suit Compl. ¶35

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

’9,006,256 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating thyroid carcinoma in a patient in need thereof, Plaintiffs allege that Zydus's 505(b)(2) application seeks approval to market its product for indications that include the treatment of thyroid cancer, which will induce infringement of the claimed method. ¶51; ¶54 col. 2:1-4
comprising administering to the patient an effective amount of an RET kinase inhibiting substance, wherein the RET kinase inhibiting substance is a compound represented by General Formula (I) or a pharmacologically acceptable salt thereof or a solvate thereof. The active ingredient of Zydus's proposed product is lenvatinib, which is the compound of Formula (I) and is alleged to be an RET kinase inhibitor. The proposed label will allegedly instruct administration of an effective amount. ¶52; ¶54 col. 4:10-23

’10,407,393 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound represented by formula (IV) or a salt thereof, Plaintiffs allege on information and belief that Zydus's proposed product is or contains lenvatinib mesylate, the salt of the compound of formula (IV). ¶61 col. 1:11-16
wherein the content of a compound represented by formula (I) is 350 ppm by mass or less. Plaintiffs allege on information and belief that Zydus's proposed product will meet this purity limitation, containing 350 parts per million or less of the specified impurity. ¶61 col. 4:1-9

Identified Points of Contention

  • Scope Questions: For the method patents (’256 and ’409), a central question will be whether the specific instructions for use in Zydus's proposed product label fall within the scope of the claims. This raises the question of whether Zydus can "carve-out" the patented indications or dosing regimens to avoid inducing infringement.
  • Technical Questions: For the composition patents (’393 and ’547), the primary dispute will be factual: does Zydus’s proposed product, as manufactured for commercial sale, actually meet the purity limitation of "350 ppm by mass or less" for the specified impurity? This will depend on the results of chemical analysis performed during discovery. Because Plaintiffs have not yet received Zydus’s confidential application materials, the infringement allegations are based on "information and belief" Compl. ¶47 Compl. ¶61

V. Key Claim Terms for Construction

Term from the ’256 Patent: "treating thyroid carcinoma"

  • Context and Importance: Practitioners may focus on this term because the scope of infringement will depend on whether Zydus's proposed product label instructs use for any condition that falls under this definition. If Zydus's label is for a subset of thyroid cancers not covered by the claim's scope, or if it successfully carves out the indication entirely, it could support a non-infringement argument.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification discusses RET mutations in various thyroid cancers, including familial medullary thyroid carcinoma and papillary thyroid carcinoma, suggesting "thyroid carcinoma" is meant to be a broad term ’256 Patent, col. 2:1-12
    • Evidence for a Narrower Interpretation: The patent’s examples focus on a human medullary thyroid carcinoma cell line ’256 Patent, col. 33:10-12 A defendant might argue this focus implies a narrower construction limited to medullary thyroid carcinoma, although this is a difficult argument given the broader claim language.

Term from the ’393 Patent: "350 ppm by mass or less"

  • Context and Importance: This term is the central limitation of the composition claim. Practitioners may focus on it because infringement will be a direct factual question of whether Zydus's product meets this purity threshold. The debate will likely center on the proper analytical method for measuring the impurity content and the statistical significance of any measurements near the 350 ppm threshold.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue that any standard, validated analytical method (e.g., HPLC) is acceptable for measuring the impurity level, as long as it is scientifically sound. The patent itself uses liquid chromatography to test purity ’393 Patent, col. 31:9-25
    • Evidence for a Narrower Interpretation: A party could argue that the term must be interpreted in light of the specific analytical methods disclosed in the patent's examples. The patent provides detailed conditions for Liquid Chromatography, which a party might argue defines the sole method for determining if the claim limitation is met ’393 Patent, col. 31:9-25

VI. Other Allegations

Indirect Infringement

  • The complaint alleges that Zydus will induce infringement of the method-of-use patents (’256 and ’409) by causing its 505(b)(2) application to be filed and, upon approval, by marketing and selling its product with a label that will instruct users to perform the patented methods Compl. ¶54 Compl. ¶81 Contributory infringement is also alleged Compl. ¶56 Compl. ¶83

Willful Infringement

  • The complaint does not contain a separate count for willful infringement. However, the allegations state that Zydus "actively and knowingly" caused the submission of its application Compl. ¶50, which could form the basis for a future willfulness claim if commercial infringement occurs post-launch. The act of infringement pleaded is primarily the "artificial" act under 35 U.S.C. § 271(e)(2)(A), which is not typically subject to willfulness findings.

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of factual evidence: for the composition patents (’393 and ’547), does Zydus’s proposed generic lenvatinib product, as it will be commercially manufactured, contain the specific impurity of formula (I) at a level of "350 ppm by mass or less"? This question will be resolved through discovery into Zydus's confidential manufacturing processes and extensive analytical testing of its product samples.
  • A second central question will be one of induced infringement: for the method-of-use patents (’256 and ’409), will the final, FDA-approved label for Zydus’s product instruct or encourage physicians to prescribe it for the patented methods of treating thyroid cancer and hepatocellular carcinoma? The case may turn on whether Zydus can successfully "carve out" these patented uses to design around the claims.
  • A potential underlying dispute will be one of claim construction and measurement: how should the term "ppm by mass" in the composition patents be measured? The outcome could depend on whether the court adopts the specific analytical methods detailed in the patent's examples or allows for other scientifically valid measurement techniques.